Search
efpeglenatide
Not yet FDA-approved.
Indications:
- diabetes mellitus with prior prior cardiovascular disease or stage 3 chronic renal function (eGFR 25-60 mL/min)
Dosage:
- once weekly injection
Adverse effects:
- gastrointestinal adverse effects may be severe
- constipation, diarrhea, nausea, vomiting, or bloating
Mechanism of action:
- GLP-1 agonist
- renal & cardiovascular protective effects
- benefits urinary albumin/creatinine ratio more than eGFR
Interactions
drug adverse effects of hypoglycemic agents
General
glucagon-like peptide 1 (GLP-1) receptor agonist; incretin mimetic; GLP-1 mimetic; GLP-1 agonist; glutide; GLP-1RA
References
- Gerstein HC, Sattar N, Rosenstock J et al
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes.
N Engl J Med 2021 Jun 28; [e-pub]
PMID: 34215025
https://www.nejm.org/doi/10.1056/NEJMoa2108269